





































hLeukemia Research 38 (2014) 149– 154
Contents lists available at ScienceDirect
Leukemia  Research
j o ur nal ho me page: www.elsev ier .com/ locate / leukres
omparison  of  24-month  outcomes  in  chelated  and  non-chelated
ower-risk  patients  with  myelodysplastic  syndromes  in  a  prospective
egistry
oger  M.  Lyonsa,b,∗, Billie  J.  Marekb,c, Carole  Paleyd, Jason  Espositod, Lawrence  Garbob,e,
icholas  DiBellab,f,  Guillermo  Garcia-Manerog
Cancer Care Centers of South Texas, San Antonio, TX, USA
US Oncology, The Woodlands, TX, USA
Texas Oncology-South Texas Cancer Center, McAllen, TX, USA
Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
New York Oncology Hematology, P.C., Albany, NY, USA
Rocky Mountain Cancer Centers, Aurora, CO, USA
University of Texas, MD  Anderson Cancer Center, Houston, TX, USA
 r  t i  c  l  e  i  n  f  o
rticle history:
eceived 8 May  2013
eceived in revised form 30 October 2013
ccepted 3 November 2013
vailable online 13 November 2013
a  b  s  t  r  a  c  t
This  5-year,  prospective  registry  enrolled  600 lower-risk  MDS  patients  (pts)  with  transfusional  iron
overload.  Clinical  outcomes  were  compared  between  chelated  and  nonchelated  pts. At baseline,  cardio-
vascular  comorbidities  were  more  common  in  non-chelated  pts,  and  MDS  therapy  was  more  common  in
chelated  pts.  At 24  months,  chelation  was  associated  with  longer  median  overall  survival  (52.2  months







No differences  in safety were  apparent  between  groups.  Limitations  of  this  analysis  included,  varying
time  from  diagnosis  and  duration  of chelation,  and  the  fact that  the  decision  to  chelate  may  have  been
inﬂuenced  by pt  clinical  status.
© 2013 The Authors. Published by Elsevier Ltd. Open access under CC BY-NC-ND license.. Introduction
Myelodysplastic syndromes (MDS) are clonal stem cell disor-
ers characterized by impaired hematopoiesis and increased risk
f acute myeloid leukemia (AML). Approximately half of patients
ith MDS  will develop severe anemia (hemoglobin level less than
0 mg/dL) and will require periodic or regular red blood cell trans-
usions [1,2]. Transfusion requirement may  lead to iron overload
nd has been associated with increased risk of death and shorter
eukemia-free survival [3,4]. Retrospective and observational stud-
es have shown that iron overload is associated with an increased
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Open access under CC BY-NC-NDrisk of cardiac, hepatic, and endocrine damage [5]. Malcovati et al.
have shown a stepwise increase in risk of death associated with
increased serum ferritin in patients with MDS. Each 500 ng/mL
increase in serum ferritin above 1000 ng/mL was associated with
a 40% increased risk of death [3]. Similarly, a multicenter, obser-
vational study by Groupe Francophone des Myélodysplasies (GFM)
sought independent prognostic factors for survival in patients who
are iron-overloaded with lower-risk MDS  [6]. Multivariate analysis
showed that transfusion requirement of more than 3 units/month
and increased International Prognostic Scoring System (IPSS) risk
status were associated with increased risk of death, whereas
adequate iron chelation (40 mg/kg/day deferoxamine 3 or more
times/week) was  associated with 70% lower risk of death. Ade-
quate chelation was  the strongest predictor of overall survival in
the French study, in which patients had a mean of 1.7 comorbidities.
Recently, prospective evidence for the beneﬁts of iron chela-
tion on hematologic parameters has been published for the oral
iron chelator deferasirox. The large evaluation of patients’ iron
chelation with Exjade® trial assessed iron-overload parameters in
transfusion-dependent patients with MDS  and showed reductions
 license.
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Table 1
Baseline demographics and MDS  risk statusa.
Variable Non-chelated n = 337 Chelated n = 263 Chelated ≥6 months n = 191
Median age (range), y 77 (47–99) 75 (21–94) 74 (21–94)
Male: female ratio 1.42:1 1.31:1 1.20:1
MDS  risk status, n (%)
World Health Organization 112 (33.2) 78 (29.7) 57 (29.8)
Refractory anemia 38 (33.9) 13 (16.7) 8 (14.0)
Refractory anemia with ring sideroblasts 34 (30.4) 40 (51.3) 32 (56.1)
Refractory cytopenia with multilineage dysplasia 20 (17.9) 12 (15.4) 8 (14.0)
Refractory cytopenia with multilineage dysplasia and ring sideroblasts 8 (7.1) 7 (9.0) 5 (8.8)
MDS  associated with isolated del (5q) 12 (10.7) 6 (7.7) 4 (7.0)
French-American-British 59 (17.5) 58 (22.1) 39 (20.4)
Refractory anemia 23 (39.0) 22 (37.9) 13 (33.3)
Refractory anemia with ring sideroblasts 17 (28.8) 28 (48.3) 21 (53.8)
Refractory anemia with excess blasts (< 11%) 19 (32.2) 8 (13.8) 5 (12.8)
International Prognostic Scoring System 166 (49.3) 127 (48.3) 95 (49.7)
Low 56 (33.7) 56 (44.1) 38 (40.0)












































va Criteria used for risk classiﬁcation was determined by accepted practice at the 
n serum ferritin, labile plasma iron, and alanine aminotransferase
ALT) levels after 1 year of chelation therapy [7]. List et al. showed
imilar results over 3 years of follow-up in heavily transfused,
ower-risk patients with MDS  [8]. At study end, serum ferritin was
educed by 37%, labile plasma iron was normalized in patients with
levated baseline levels, and transferrin saturation was  reduced
o 67% from a baseline of 91%. Improved ALT levels were sig-
iﬁcantly correlated with reduced serum ferritin in the study by
ist et al.
However, prospective data on the relationship between chela-
ion, morbidity, and mortality are lacking. The goal of this registry
s to evaluate the association between chelation and clinical out-
omes in lower-risk MDS  patients. We  report 24-month data from
n ongoing, 5-year registry of lower-risk patients with MDS  in the
nited States. This registry provides prospectively collected data
n clinical and safety parameters in chelated versus non-chelated,
ron-overloaded, transfusion-dependent, lower-risk patients with
DS.
. Patients and methods
This study is a prospective, 5-year, observational registry of 600 lower-risk
atients with MDS and iron overload from 118 centers in the United States (9 aca-
emic sites; 109 community cancer centers) that enrolled patients over a 2-year
eriod. The ﬁrst patient ﬁrst visit was completed on December 20, 2010. The cur-
ent  analysis presents 24-month data from the registry; this represents a composite
f  data from patients who  have completed up to 24 months on the registry. Patient
aseline characteristics and study outcomes were analyzed according to their chela-
ion status (non-chelated, chelated, and chelated ≥6 months cumulatively). Chelated
atients were deﬁned as those patients who received chelation at any point. In addi-
ion, a planned subanalysis was performed for patients who received ≥6 months
f  cumulative chelation because this duration was thought to provide an ade-
uate treatment period. The chelated ≥6 months group was  included in the overall
helated group. Follow-up occurred every 6 months for up to 60 months or death.
ssessments included demographics, survival, causes of death, leukemic transfor-
ation, serum ferritin, concomitant illnesses, MDS  therapy, ongoing transfusion
equirements, and safety.
Patients were aged 18 years or older with transfusional iron overload (serum
erritin more than 1000 ng/mL, 20 or more packed red blood cell units, or ongo-
ng  transfusion requirement of 6 or more units every 12 weeks) and lower-risk
DS  by IPSS, World Health Organization (WHO), and/or French-American-British
FAB) criteria. Approved and experimental MDS  therapies were permitted. Adverse
vents were documented occurring on study and during the 4 weeks after stopping
helation therapy. This study was  conducted in accordance with the declaration of
elsinki. All enrolled patients gave written informed consent.
Data are summarized according to demographic and baseline characteristics,
afety observations, and outcome measurements. Summary statistics were calcu-
ated for continuous variables, and descriptive statistics were calculated for discrete
ariables and laboratory tests.f initial diagnosis. MDS, myelodysplastic syndromes.
3. Results
3.1. Baseline characteristics
Median age was  similar across patient groups (non-chelated, 77
years [range, 47–99]; chelated, 75 years [range, 21–94]; chelated ≥6
months, 74 years [range, 21–94]; Table 1). All groups had a larger
percentage of men  than of women, although the difference was
noted less in the chelated groups. Overall, 86.7% of patients were
Caucasian, 6.2% were Hispanic, 5.5% were African American, 1.0%
were Asian, and 0.3% each were Native American or other. In all,
82% of patients were enrolled at community cancer centers.
Approximately half of patients were classiﬁed lower-risk MDS
by IPSS criteria, approximately 30% were classiﬁed lower-risk by
WHO, and approximately 20% were classiﬁed lower-risk by FAB.
The MDS  risk status proﬁles were similar across groups except
that a larger percentage of non-chelated patients were classiﬁed as
intermediate-1 risk by IPSS criteria (non-chelated, 66.3%; chelated,
55.9%; and chelated ≥6 months, 60.0%), having refractory ane-
mia  by WHO  criteria (non-chelated, 33.9%; chelated, 16.7%; and
chelated ≥6 months, 14.0%), and having refractory anemia with
excess blasts by FAB criteria (non-chelated, 32.2%; chelated, 13.8%;
and chelated ≥6 months, 12.8%).
Baseline cardiac and vascular comorbidities were more common
in the non-chelated group (Table 2). Cardiac conditions included
coronary artery disease, cardiomyopathy, rhythm abnormalities,
structural abnormalities, and infectious/inﬂammatory conditions.
Use of MDS  therapies was more common in chelated patients.
Overall, 287 (85.2%), 243 (92.4%), and 175 patients (91.6%) in the
non-chelated, chelated, and chelated ≥6 months groups, respec-
tively, had received MDS  therapy prior to or at enrollment. Growth
factor use trended higher among chelated patients. Erythropoietin
was used by 65.3% of non-chelated, 76.8% of chelated, and 80.1% of
chelated ≥6 months groups; granulocyte colony-stimulating fac-
tor (GCSF) was  used by 18.1% of non-chelated, 24.0% of chelated,
and 25.7% of chelated ≥6 months groups. Low-dose chemother-
apy/immunomodulator use, with the exception of hydroxyurea,
trended higher in chelated patients. Azacitidine use in non-
chelated, chelated, and chelated ≥6 months groups was 40.1%,
51.7%, and 55.0%; decitabine use was  26.1%, 31.2%, and 30.9%;
lenalidomide use was 16.3%, 36.5%, and 39.8%; thalidomide use was
3.6%, 7.2%, and 7.9%; and hydroxyurea use was  3.6%, 2.3%, and 2.6%,
respectively. Units transfused trended higher in the chelated group.
Median (range) lifetime units transfused before the study were 20
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Table 2
Baseline concomitant conditions.
Variable, n (%)a Non-chelated n = 337 Chelated n = 263 Chelated ≥6 months n = 191
Cardiac 173 (51.3) 92 (35.0) 59 (30.9)
Vascular 201 (59.6) 125 (47.5) 88 (46.1)
Endocrine 146 (43.3) 100 (38.0) 66 (34.6)
Hepatobiliary 10 (3.0) 10 (3.8) 9 (4.7)
Gastrointestinal 127 (37.7) 92 (35.0) 64 (33.5)
Musculoskeletal 114 (33.8) 70 (26.6) 45 (23.6)
Neoplasms 42 (12.5) 31 (11.8) 23 (12.0)
Respiratory 42 (12.5) 27 (10.3) 15 (7.9)
Neurologic/psychiatric 36 (10.7) 38 (14.4) 28 (14.7)
Renal  7 (2.1) 3 (1.1) 1 (0.5)
Ophthalmologic 53 (15.7) 27 (10.3) 17 (8.9)
Audiologic 30 (8.9) 27 (10.3) 17 (8.9)
Infectious disease 23 (6.8) 18 (6.8) 13 (6.8)
a A patient is counted once at system organ class or condition level if one or more conditions are reported.
Fig. 1. Overall survival. Chelated patients had longer overall survival compared with
non-chelated patients. Kaplan–Meier curves for overall survival showed median




























Fig. 2. Causes of death (n = 278). There were 171 (50.7%), 107 (40.7%), and 70 deaths
(36.6%) in non-chelated, chelated, and chelated ≥6 months groups, respectively,
(p  = .0018 for non-chelated vs. chelated ≥6 months groups). Overall causes of death
are  shown. No statistical difference in causes of death was observed among groups,
except for a higher rate of death from non-myeloid malignancy in non-chelatedhelated, and chelated ≥6 months groups was  52.2 (24.0, 136.2), 99.3 (54.1, not
ttained [NA]), and 104.4 months (63.4, NA), respectively (p < .0001 for non-chelated
s. both chelated groups).
0–250), 39 (0–620), and 44 (0–620) in the non-chelated, chelated,
nd chelated ≥6 months groups, respectively.
.2. Interim analysis of patients completing 24 months on the
egistry
At follow-up, 249 patients (41.5%) remained on study and 351
58.5%) discontinued due to death (278 [46.3%]), lost to follow-up
51 [8.5%]), and other (22 [3.7%]).
Overall survival in each patient group was calculated from the
ate of MDS  diagnosis. Kaplan–Meier analysis showed that median
25th, 75th percentile) time to death from MDS  diagnosis was  sig-
iﬁcantly longer in the chelated groups (Fig. 1). Patients in the
on-chelated, chelated, and chelated ≥6 months groups survived
 median of 52.2 (24.0, 136.2), 99.3 (54.1, not attained [NA]), and
04.4 months (63.4, NA) (p < .0001 for non-chelated vs. chelated
roups), respectively. In the IPSS low-risk group, median (range)
verall survival was 53.6 (4.1, 66.3) months for non-chelated
atients and 98.7 (12.8, 103.8) months for chelated ≥6 months
atients (p = .028). In the IPSS intermediate-1 group, overall sur-
ival was 44.7 (5.5, 151.6) for non-chelated patients and 70.0 (12.5,
3.4) months for chelated ≥6 months patients (p = .013).
There were 171 (50.7%), 107 (40.7%), and 70 deaths (36.6%) in
on-chelated, chelated, and chelated ≥6 months groups (p = 0.0018
or non-chelated vs. chelated ≥6 months groups), respectively.
ore than half of the deaths in the study could be attributed
o MDS/AML (43.9%) and cardiac causes (15.5%; Fig. 2). For com-
ined MDS/AML deaths, approximately 66% were attributed to MDS
nd 34% were attributed to AML. Given the substantial overlap inpatients (p = .023 for non-chelated vs. chelated ≥6 months groups). MDS, myelodys-
plastic syndromes; AML, acute myeloid leukemia; CVA, cardiovascular accident;
GvHD, graft-versus-host disease.
disease features and the absence of bone marrow biopsies near
demise in most patients, it was  often difﬁcult to distinguish MDS
progression from progression to AML  as the ﬁnal cause of death.
An increased number and percentage of deaths secondary to non-
myeloid malignancy among non-chelated patients was the only
signiﬁcant difference in causes of death among treatment groups
(p = .023).
The percentage of patients who  progressed to AML  trended
higher in non-chelated patients. In all, 30 (8.9%), 12 (4.6%), and 10
patients (5.2%) progressed to AML  in the non-chelated, chelated,
and chelated ≥6 months groups, respectively. Time from MDS  diag-
nosis to progression to AML  trended longer in both chelated groups
(Fig. 3). Mean (standard deviation) time to progression was  27.3
(20.3), 40.6 (25.3), and 40.8 months (27.0) in the non-chelated,
chelated, and chelated ≥6 months groups, respectively.
Baseline ferritin levels trended higher in chelated versus non-
chelated patients (Table 3). There was  no clear trend in ferritin
levels among patient groups over the course of the 24 months
studied.
Newly diagnosed or progressive cardiac conditions after study
entry trended higher in the non-chelated group (155, 46.0%) versus
the chelated (113, 43.0%) and chelated ≥6 months groups (76,
39.8%) (p = .167, non-chelated vs. chelated ≥6  months group). The
frequency of other conditions appearing on study was  similar
among groups, including endocrine and hepatic conditions; renal,
ocular, and auditory dysfunction; and new cytopenias.
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Table 3
Serum ferritina.
Serum ferritin (ng/mL) Non-chelated n = 337 Chelated n = 263 Chelated ≥6 months n = 191
Baseline
n 258 232 169
Median (range) 1353 (3–7379) 1513 (81–16,422) 1500 (81–16,422)
6  months
n  82 149 117
Median (range) 1380 (22–6250) 1562 (30–10,646) 1505 (30–10,646)
12  months
n 61 140 111
Median (range) 1437 (5–11,647) 1962 (188–20,966) 1740 (188–20,966)
18  months
n 40 88 72
Median  (range) 2000 (3–6901) 1610 (184–26,097) 1609 (184–26,097)
24  months
n 15 
Median  (range) 1540 (39–16,458) 
a No consistent trend was  observed in serum ferritin levels.
Fig. 3. Progression to AML. Time to progression to AML  trended longer in chelated
patients. Kaplan–Meier curves for progression to AML  showed a mean (standard
























sn  the non-chelated, chelated, and chelated ≥6 months groups, respectively. Curves
or  the chelated groups were practically identical and overlapped. No statistical
ifference was  observed among groups. AML, acute myeloid leukemia.
The percentage of patients who received MDS  therapies on study
as similar across groups. In the entire registry population, eryth-
opoietin and GCSF were used by 46.0% and 12.3% of patients,
espectively. Azacitidine, decitabine, lenalidomide, thalidomide,
nd hydroxyurea were used by 28.3%, 17.5%, 11.2%, 0.3%, and
.7% of patients, respectively. Cumulative duration of MDS  therapy
n study trended longer in chelated (median, 15 months [range,
.1–39]) versus non-chelated patients (median, 9.9 months [range,
.03–37]). Patients had received a median of 26 units (range, 0–620)
ransfused prior to enrollment and 1.85 units (range, 0–10.18) dur-
ng any 4-week period on study.
In all, 29.1% of patients were receiving the following iron
helation therapy at baseline: 25.2% received deferasirox and
.3% received deferoxamine. The percentage of chelated patients
ncreased to 37% on study, in which 32.2% received deferasirox
nd 7.2% received deferoxamine. Some patients received different
helation therapies during the course of their treatment. Median
range) duration of treatment in all patients who received chelation
herapy was 17.4 (0.03, 146.53) months in chelated patients vs. 21.9
6.18, 146.53) months in patients chelated ≥6 months (p < .0001).
.3. SafetyLaboratory assessments for renal and hepatic function were per-
ormed at baseline and every 6 months thereafter. Baseline median
erum creatinine levels (mg/dL) were in the normal range (1.1, 1.0,52 45
1538 (363–8768) 1501 (363–8768)
and 1.0 in non-chelated, chelated, and chelated ≥6 months patients,
respectively) and were not different from baseline at any assess-
ment (p > .3, all comparisons). Similarly, baseline liver transaminase
levels were in the normal range. Median aspartate aminotrans-
ferase levels were 22.0 IU/L across all patient groups, and median
ALT levels (IU/L) were 24.0, 29.5, and 30.0 in non-chelated, chelated,
and chelated ≥6 months patients, respectively. Liver transaminase
values did not increase from baseline at any assessment (p > .1, all
comparisons). Safety assessments did not reveal any new concerns.
4. Discussion
Survival and clinical outcomes in chelated patients with MDS
have not been evaluated prospectively in large, randomized trials.
Nevertheless, National Comprehensive Cancer Network guide-
lines recommend the use of chelation therapy in iron-overloaded,
lower-risk patients with MDS  because of their longer predicted sur-
vival and the potential for developing organ damage secondary
to iron overload [9]. However, it is difﬁcult to determine the
contribution of iron toxicity to morbidity and mortality in these
patients because of their advanced age and the high prevalence
of comorbidities driving non-leukemic mortality [10,11]. This reg-
istry provides prospective information on the relationship between
chelation therapy and survival and clinical outcomes in lower-risk,
transfusion-dependent patients with MDS. Patients in the registry
were treated predominantly in community cancer centers. There-
fore, the study reﬂects care received by the majority of patients
with MDS  in the United States.
Median overall survival was  statistically longer in chelated vs.
non-chelated patients. Median time to death from MDS  diagno-
sis was  approximately half as long in non-chelated compared with
chelated and chelated ≥6 months patients (52.2, 99.3, and 104.4
months, respectively; p < .0001). This pattern was also observed
when patients were stratiﬁed by IPSS risk status, which suggests
a survival beneﬁt from chelation therapy can be realized across
IPSS lower-risk patient groups. In low-risk patients, median over-
all survival in the chelated ≥6 months group vs. the non-chelated
group was  98.7 vs. 53.6 months (p = .028). Similarly in Intermediate-
1-risk patients, median survival in the chelated ≥6 months group
vs. the non-chelated group was 70.0 vs. 44.7 months (p = .013). An
observational study in patients with MDS  by Rose et al. showed
similar results with median time to death from diagnosis of 53
and 124 months in non-chelated and chelated patients, respec-
tively (p < .0003) [6]. It must be kept in mind in interpreting these
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he patient’s clinical status. Thus, the improved overall survival
n chelated vs. non-chelated patients may  have reﬂected a better
nitial clinical status as well as a potential beneﬁt of chelation.
The rate of death from malignancies other than AML  in this
egistry was only 4.3%. In comparing the chelated ≥6 months vs.
on-chelated groups, there was a statistically signiﬁcant difference
n the rate of deaths due to non-myeloid malignancy (p = .023).
hile there were no other statistically signiﬁcant differences in
auses of deaths, between chelated ≥6 months and non-chelated
atients, the percentage of patients dying from cardiac events,
nfection, and MDS/AML was higher in the non-chelated group. In
he study by Rose et al., no differences in causes of death were seen
6]. Cardiac events, infections, and MDS/AML were the most com-
on causes of death in this registry and the study by Rose et al. [6].
he lack of multivariate analysis to account for the contribution
f comorbid conditions to mortality in either study may  confound
ause of death analysis.
There was a trend toward shorter AML-free survival in non-
helated patients over the 2-year analysis period. In all, 8.9%,
.6%, and 5.2% of non-chelated, chelated, and chelated ≥6 months
atients progressed to AML, respectively. The observational study
y Rose et al. also showed a nonsigniﬁcant trend toward shorter
ML-free survival in non-chelated patients. At 2.5 years, 34% of
on-chelated and 17% of chelated patients had progressed to AML
6]. Kaplan–Meier analysis in the present study suggested that time
o AML  transformation may  have been longer in chelated versus
on-chelated patients (41 vs. 27 months, respectively).
In comparing baseline characteristics between the chelated and
on-chelated patients, median age and risk stratiﬁcation were sim-
lar; however, prevalence of cardiovascular disease at baseline was
igher in the non-chelated group. Patients were classiﬁed lower-
isk MDS  by either IPSS, WHO, or FAB criteria, but some differences
n subtype of anemia were observed among groups. The choice of
isk classiﬁcation criteria was determined by accepted practice at
he time of initial diagnosis. Baseline serum ferritin levels trended
igher in chelated versus non-chelated patients and remained
igher in the chelated group over the course of the study. This trend
ay  reﬂect the higher transfusion burden in chelated patients and
hus their selection for chelation therapy. No clear pattern in serum
erritin levels was observed over the course of the study. These
esults are consistent with retrospective observations, in which
ean serum ferritin levels did not predictably decrease after the
nitiation of chelation therapy [12]. However, signiﬁcant reductions
n serum ferritin levels were seen in interventional trials [7,13].
his disparity may  reﬂect the different intensities and duration of
helation in a registry compared with a clinical trial.
Cardiac and vascular conditions were more common in non-
helated patients at baseline. The same trend was observed for
ardiac conditions emerging while on study, in which 46%, 43%, and
0% of non-chelated, chelated, and chelated ≥6 months patients
eveloped cardiac conditions, respectively (p = .167). The emer-
ence of endocrine, hepatic, and renal conditions over the 2-year
tudy was similar between chelated and non-chelated patients. The
mergence of ocular and auditory dysfunction and new cytopenias
as also similar between the chelated and non-chelated groups.
here was a trend toward higher use of MDS-speciﬁc therapies in
helated patients compared with non-chelated patients. This trend
oward higher use of MDS  therapies in chelated patients may  have
ontributed to their improved overall survival.
No speciﬁc safety concerns related to the use of chelation ther-
py were observed over the 24-month study period.
Limitations of these data include the fact that assessments were
ptional; therefore, some data points were not captured for every
atient. In addition, there may  have been some clinical bias in
electing patients for chelation. Patients with better overall perfor-
ance status and predicted longer survival may  be more likely toearch 38 (2014) 149– 154 153
receive chelation. Potentially, this may  have impacted clinical out-
comes. It is unclear whether MDS  therapy used in these patients
affected clinical outcomes. Another question is whether the dif-
ferences in baseline characteristics among the groups contributed
to longer overall survival or the trend toward longer AML-free sur-
vival. Study strengths include the large number of patients enrolled
in the registry along with the large number of participating study
sites, which is likely to represent the heterogeneity of clinical
practice.
The results of this registry are consistent with previous retro-
spective studies that show an association between chelation and
increased overall survival in patients with MDS. Ongoing follow-
up for the 5-year duration of the registry will provide further data
on differences in outcomes between chelated and non-chelated
patients.
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